Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

…, Y Tanaka, RM Gordon, C Shu, K Fei… - Annals of the …, 2022 - ard.bmj.com
Objective Evaluate the efficacy and safety of ustekinumab, an anti-interleukin-12/23 p40
antibody, in a phase 3, randomised, placebo-controlled study of patients with active systemic …

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study

…, G Karpouzas, S Sheng, W Xu, R Rao, K Fei… - Annals of the …, 2017 - ard.bmj.com
Objectives Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology.
Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively …

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled …

C Bao, F Huang, MA Khan, K Fei, Z Wu, C Han… - …, 2014 - academic.oup.com
Objective. The aim of this study was to assess the efficacy and safety of golimumab in Chinese
patients with active AS. Methods. Two hundred and thirteen patients were randomized in …

Epithelial morphogenesis in hydra requires de novo expression of extracellular matrix components and matrix metalloproteinases

H Shimizu, X Zhang, J Zhang, A Leontovich, K Fei… - 2002 - journals.biologists.com
As a member of the phylum Cnidaria, the body wall of hydra is organized as an epithelium
bilayer (ectoderm and endoderm) with an intervening extracellular matrix (ECM). Previous …

Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double‐blind, placebo‐controlled crossover …

…, BH Hahn, GC Tsokos, P Lipsky, K Fei… - Arthritis & …, 2020 - Wiley Online Library
Objective To evaluate the efficacy and safety of ustekinumab through 1 year in a phase II
trial in patients with systemic lupus erythematosus ( SLE ). Methods Eligible patients were …

Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease

…, X Fan, SK Aurora, JL Brandes, K Fei… - … : The Journal of …, 2012 - Wiley Online Library
Objective.— To evaluate the efficacy of telcagepant in patients with migraine and coronary
artery disease. Background.— Calcitonin gene‐related peptide receptor antagonists, such as …

Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study

…, GC Tsokos, P Lipsky, RM Gordon, K Fei… - The Journal of …, 2022 - jrheum.org
Objective To evaluate the long-term efficacy and safety of ustekinumab through 2 years in
patients with active systemic lupus erythematosus (SLE). Methods This was a placebo-…

Identification and characterization of hydra metalloproteinase 2 (HMP2): a meprin-like astacin metalloproteinase that functions in foot morphogenesis

L Yan, K Fei, J Zhang, S Dexter… - Development, 2000 - journals.biologists.com
Several members of the newly emerging astacin metalloproteinase family have been shown
to function in a variety of biological events, including cell differentiation and morphogenesis …

Hydra metalloproteinase 1: a secreted astacin metalloproteinase whose apical axis expression is differentially regulated during head regeneration

L Yan, A Leontovich, K Fei, MP Sarras Jr - Developmental Biology, 2000 - Elsevier
The newly emerging astacin metalloproteinase family comprises multiple members with diverse
functions. Most recently, the development-related functions have been attributed to both (…

Identification and characterization of the epithelial polarity receptor ”Frizzled” in Hydra vulgaris

S Minobe, K Fei, L Yan, MP Sarras Jr… - Development genes and …, 2000 - Springer
The Wnt signaling pathway plays an important role in the specification of cell patterning
during development in many species. Here we report the isolation and characterization of a …